In this edition of Market Checkup, health-care analysts David Williamson and Max Macaluso discuss today's biggest health-care news, including Amgen's multibillion-dollar acquisition of oncology specialist Onyx Pharmaceuticals, Rigel Pharmaceuticals' latest clinical trial disappointment, new allegations of a big pharma's misconduct in China, and a new opportunity in Eli Lilly's animal health division.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Snap Is Laying Off Employees in One of Its Most Important Divisions
Snapchat's content team just got a bit smaller. What does it mean for investors?
Delta Air Lines Gets Ready to Expand Again in Seattle and Boston
Seattle and Boston have been two of Delta's most important growth markets in recent years. That focus will continue in 2018.
Once Left for Dead, This Hotly Contested Oil Pipeline Now Has Enough Support to Move Forward
TransCanada has secured enough shippers to proceed with the Keystone XL Pipeline.